Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy. (2022)
Attributed to:
Peptide conjugated oligonucleotides for a phase I/IIa clinical trial in Spinal Muscular Atrophy
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1172/jci.insight.154142
PubMed Identifier: 36346674
Publication URI: http://europepmc.org/abstract/MED/36346674
Type: Journal Article/Review
Volume: 7
Parent Publication: JCI insight
Issue: 24
ISSN: 2379-3708